HBPCF (Helix BioPharma) Change In Receivables : $0.02 Mil (TTM As of Jan. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Change In Receivables?

Helix BioPharma's change in receivables for the quarter that ended in Jan. 2025 was $0.00 Mil. It means Helix BioPharma's Accounts Receivable declined by $0.00 Mil from Oct. 2024 to Jan. 2025 .

Helix BioPharma's change in receivables for the fiscal year that ended in Jul. 2024 was $0.01 Mil. It means Helix BioPharma's Accounts Receivable declined by $0.01 Mil from Jul. 2023 to Jul. 2024 .

Helix BioPharma's Accounts Receivable for the quarter that ended in Jan. 2025 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Helix BioPharma's liquidation value for the three months ended in Jan. 2025 was $-0.18 Mil.

Helix BioPharma Change In Receivables Historical Data

The historical data trend for Helix BioPharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Change In Receivables Chart

Helix BioPharma Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Change In Receivables

Get a 7-Day Free Trial

0.05

-0.14

0.06

0.16

0.01

Helix BioPharma Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Change In Receivables	Get a 7-Day Free Trial															-	-0.02	0.03	0.01	-

Helix BioPharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.

Helix BioPharma (OTCPK:HBPCF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Helix BioPharma's Days Sales Outstanding for the quarter that ended in Jan. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Helix BioPharma's accounts receivable are only considered to be worth 75% of book value:

Helix BioPharma's liquidation value for the quarter that ended in Jan. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.387	-	1.571	+	0.75 * 0	+	0.5 * 0
=	-0.18

Helix BioPharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

HBP0:Germany HBP:Canada

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.